Phaseline

Targets › SLC5A5

SLC5A5 (Sodium/iodide cotransporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Sodium:iodide symporter that mediates the transport of iodide into the thyroid gland. Can also mediate the transport of chlorate, thiocynate, nitrate and selenocynate. (UniProt, Q92911)

Open in Phaseline: the race on SLC5A5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCombination radiotherapy and radiopharmaceutical therapy (CXRPT): external beam
Targeted radiotherapy combining external beam radiation and radioactive iodine-131 (RAI/13
SLC5A5Phase 1Recurrent Thyroid CancerDec 2027

Conditions

Recurrent Thyroid Cancer (1)

Modalities

–

Companies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.